Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.

Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ.

Genes Dev. 1995 Mar 15;9(6):650-62.

2.
5.

Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.

Luo Y, Hurwitz J, Massagué J.

Nature. 1995 May 11;375(6527):159-61.

PMID:
7753174
6.

Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.

Hsieh FF, Barnett LA, Green WF, Freedman K, Matushansky I, Skoultchi AI, Kelley LL.

Blood. 2000 Oct 15;96(8):2746-54.

7.

Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.

Orlow I, Iavarone A, Crider-Miller SJ, Bonilla F, Latres E, Lee MH, Gerald WL, Massagué J, Weissman BE, Cordón-Cardó C.

Cancer Res. 1996 Mar 15;56(6):1219-21.

8.

Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome.

Bhuiyan ZA, Yatsuki H, Sasaguri T, Joh K, Soejima H, Zhu X, Hatada I, Morisaki H, Morisaki T, Mukai T.

Hum Genet. 1999 Mar;104(3):205-10.

PMID:
10323243
9.

Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse.

Hatada I, Mukai T.

Nat Genet. 1995 Oct;11(2):204-6.

PMID:
7550351
10.

Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.

Goubin F, Ducommun B.

Oncogene. 1995 Jun 15;10(12):2281-7.

PMID:
7784076
11.

High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.

Bourcigaux N, Gaston V, Logié A, Bertagna X, Le Bouc Y, Gicquel C.

J Clin Endocrinol Metab. 2000 Jan;85(1):322-30.

PMID:
10634406
12.

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ.

Cell. 1993 Nov 19;75(4):805-16.

PMID:
8242751
13.

Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.

Chen IT, Akamatsu M, Smith ML, Lung FD, Duba D, Roller PP, Fornace AJ Jr, O'Connor PM.

Oncogene. 1996 Feb 1;12(3):595-607.

PMID:
8637717
14.

Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.

Yan Y, Frisén J, Lee MH, Massagué J, Barbacid M.

Genes Dev. 1997 Apr 15;11(8):973-83.

15.
16.

Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Reynisdóttir I, Polyak K, Iavarone A, Massagué J.

Genes Dev. 1995 Aug 1;9(15):1831-45.

17.

Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.

Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J.

Oncogene. 2000 Feb 3;19(5):670-9.

18.

A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.

Coats S, Whyte P, Fero ML, Lacy S, Chung G, Randel E, Firpo E, Roberts JM.

Curr Biol. 1999 Feb 25;9(4):163-73.

19.
20.

p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts.

Takahashi K, Kobayashi T, Kanayama N.

Mol Hum Reprod. 2000 Nov;6(11):1019-25.

PMID:
11044465

Supplemental Content

Support Center